231 related articles for article (PubMed ID: 23225018)
21. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy.
Muchtar E; Buadi FK; Dispenzieri A; Gertz MA
Acta Haematol; 2016; 135(3):172-90. PubMed ID: 26771835
[TBL] [Abstract][Full Text] [Related]
22. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
[TBL] [Abstract][Full Text] [Related]
23. New insights and modern treatment of AL amyloidosis.
Chaulagain CP; Comenzo RL
Curr Hematol Malig Rep; 2013 Dec; 8(4):291-8. PubMed ID: 24026941
[TBL] [Abstract][Full Text] [Related]
24. New and developing therapies for AL amyloidosis.
Zumbo G; Sadeghi-Alavijeh O; Hawkins PN; Fontana M
Expert Opin Pharmacother; 2017 Feb; 18(2):139-149. PubMed ID: 28002971
[TBL] [Abstract][Full Text] [Related]
25. [AL-amyloidosis and its treatment by eliminating the precursor protein].
Verbeek DE; Hazenberg BP; Jager PL; Kremer Hovinga TK
Ned Tijdschr Geneeskd; 2007 Sep; 151(37):2021-6. PubMed ID: 17929708
[TBL] [Abstract][Full Text] [Related]
26. Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation.
Comenzo RL; Wally J; Kica G; Murray J; Ericsson T; Skinner M; Zhang Y
Br J Haematol; 1999 Sep; 106(3):744-51. PubMed ID: 10468868
[TBL] [Abstract][Full Text] [Related]
27. Quantitative analysis of serum free light chains. A new marker for the diagnostic evaluation of primary systemic amyloidosis.
Abraham RS; Katzmann JA; Clark RJ; Bradwell AR; Kyle RA; Gertz MA
Am J Clin Pathol; 2003 Feb; 119(2):274-8. PubMed ID: 12579999
[TBL] [Abstract][Full Text] [Related]
28. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts.
Liao R; Jain M; Teller P; Connors LH; Ngoy S; Skinner M; Falk RH; Apstein CS
Circulation; 2001 Oct; 104(14):1594-7. PubMed ID: 11581134
[TBL] [Abstract][Full Text] [Related]
29. Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).
Dispenzieri A; Merlini G; Comenzo RL
Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):6-11. PubMed ID: 18162215
[TBL] [Abstract][Full Text] [Related]
30. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004.
Gertz MA; Comenzo R; Falk RH; Fermand JP; Hazenberg BP; Hawkins PN; Merlini G; Moreau P; Ronco P; Sanchorawala V; Sezer O; Solomon A; Grateau G
Am J Hematol; 2005 Aug; 79(4):319-28. PubMed ID: 16044444
[TBL] [Abstract][Full Text] [Related]
31. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
Lachmann HJ; Gallimore R; Gillmore JD; Carr-Smith HD; Bradwell AR; Pepys MB; Hawkins PN
Br J Haematol; 2003 Jul; 122(1):78-84. PubMed ID: 12823348
[TBL] [Abstract][Full Text] [Related]
32. [Fibril-forming proteins: the amyloidosis. New hopes for a disease that cardiologists must know].
Arbustini E; Gavazzi A; Merlini G
Ital Heart J Suppl; 2002 Jun; 3(6):590-7. PubMed ID: 12116807
[TBL] [Abstract][Full Text] [Related]
33. Toxic megacolon: a life-threatening complication of high-dose therapy and autologous stem cell transplantation among patients with AL amyloidosis.
Hayes-Lattin BM; Curtin PT; Fleming WH; Leis JF; Stepan DE; Schubach S; Maziarz RT
Bone Marrow Transplant; 2002 Sep; 30(5):279-85. PubMed ID: 12209349
[TBL] [Abstract][Full Text] [Related]
34. Future directions in the clinical management of amyloid light-chain amyloidosis.
Haider S; Ahmad N; Anaissie E; Driscoll JJ
Leuk Lymphoma; 2014 Oct; 55(10):2241-51. PubMed ID: 24359238
[TBL] [Abstract][Full Text] [Related]
35. Gastrointestinal perforation early after peripheral blood stem cell transplantation for AL amyloidosis.
Schulenburg A; Kalhs P; Oberhuber G; Reiter E; Base W; Greinix HT
Bone Marrow Transplant; 1998 Aug; 22(3):293-5. PubMed ID: 9720746
[TBL] [Abstract][Full Text] [Related]
36. Free light chain testing for the diagnosis, monitoring and prognostication of AL amyloidosis.
Mollee P; Merlini G
Clin Chem Lab Med; 2016 Jun; 54(6):921-7. PubMed ID: 26812792
[TBL] [Abstract][Full Text] [Related]
37. Immunoglobulin light and heavy chain amyloidosis AL/AH: renal pathology and differential diagnosis.
Picken MM
Contrib Nephrol; 2007; 153():135-55. PubMed ID: 17075228
[TBL] [Abstract][Full Text] [Related]
38. How we treat systemic light-chain amyloidosis.
Chaulagain CP; Comenzo RL
Clin Adv Hematol Oncol; 2015 May; 13(5):315-24. PubMed ID: 26352777
[TBL] [Abstract][Full Text] [Related]
39. Decrease of B-type natriuretic peptide to less than 200 pg/mL predicts longer survival in cardiac immunoglobulin light chain amyloidosis.
Ishiguro K; Hayashi T; Igarashi T; Maruyama Y; Ikeda H; Ishida T; Shinomura Y
Int J Hematol; 2015 Aug; 102(2):200-4. PubMed ID: 26016720
[TBL] [Abstract][Full Text] [Related]
40. Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?
Bahlis NJ; Lazarus HM
Bone Marrow Transplant; 2006 Jul; 38(1):7-15. PubMed ID: 16715110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
